Stockreport

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First-in-Class Neuroprotective Candidate for Optic Neuritis [TheStreet.com]

Oculis Holding AG  (OCS) 
PDF ZUG, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough in [Read more]